Bioventus (NYSE:BVS) Stock Price Down 4.2%

Bioventus Inc. (NYSE:BVS)’s stock price traded down 4.2% on Wednesday . The company traded as low as $7.54 and last traded at $7.57. 114,139 shares changed hands during trading, a decline of 65% from the average session volume of 322,632 shares. The stock had previously closed at $7.90.

Analyst Upgrades and Downgrades

BVS has been the topic of a number of recent research reports. Craig Hallum boosted their target price on Bioventus from $9.00 to $12.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Canaccord Genuity Group upped their target price on Bioventus from $8.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday.

Bioventus Stock Performance

The stock has a market cap of $687.16 million, a price-to-earnings ratio of -24.80 and a beta of 0.84. The company has a debt-to-equity ratio of 1.63, a current ratio of 1.53 and a quick ratio of 0.97. The stock’s 50-day moving average is $6.72 and its 200-day moving average is $5.69.

Bioventus (NYSE:BVS) last released its quarterly earnings data on Tuesday, August 6th. The company reported $0.19 EPS for the quarter, topping analysts’ consensus estimates of $0.07 by $0.12. Bioventus had a positive return on equity of 11.91% and a negative net margin of 4.14%. The business had revenue of $151.22 million during the quarter, compared to the consensus estimate of $137.70 million. During the same period in the prior year, the firm posted $0.14 EPS. Analysts anticipate that Bioventus Inc. will post 0.27 EPS for the current fiscal year.

Insiders Place Their Bets

In other Bioventus news, SVP Anthony D’adamio sold 11,308 shares of the company’s stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $5.84, for a total transaction of $66,038.72. Following the completion of the sale, the senior vice president now directly owns 81,630 shares in the company, valued at $476,719.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, SVP Anthony D’adamio sold 11,308 shares of the stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $5.84, for a total value of $66,038.72. Following the completion of the sale, the senior vice president now owns 81,630 shares in the company, valued at $476,719.20. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Mark Leonard Singleton sold 9,219 shares of the stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $5.57, for a total value of $51,349.83. Following the completion of the sale, the chief financial officer now owns 84,895 shares of the company’s stock, valued at approximately $472,865.15. The disclosure for this sale can be found here. Insiders sold 40,184 shares of company stock worth $230,591 over the last three months. 32.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Bioventus

Large investors have recently modified their holdings of the stock. Acadian Asset Management LLC bought a new stake in shares of Bioventus in the first quarter worth $28,000. Lazard Asset Management LLC bought a new position in Bioventus during the 1st quarter valued at $40,000. HB Wealth Management LLC acquired a new position in Bioventus during the 2nd quarter worth $60,000. SG Americas Securities LLC bought a new stake in shares of Bioventus in the 1st quarter worth about $66,000. Finally, Burns Matteson Capital Management LLC acquired a new stake in shares of Bioventus in the 2nd quarter valued at about $67,000. Institutional investors and hedge funds own 62.94% of the company’s stock.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.